Park Byung Cheol, Lim Hyun Jung, Kim Byung Soo, Lee Weon Ju, Kim Do Won, Lee Seok-Jong
Department of Dermatology, Ajou University Hospital, Suwon, Korea.
Ann Dermatol. 2009 Feb;21(1):60-2. doi: 10.5021/ad.2009.21.1.60. Epub 2009 Feb 28.
As more rheumatologists and dermatologists have begun to use biological agents such as TNF-alpha blocker, they have confronted an unexpected complication: psoriasis was paradoxically aggravated or induced by the TNF-alpha blocker. Although it is not a common complication of TNF-alpha blocker, this aggravation may be more common than previously thought. To our knowledge, most reports about TNF-alpha blocker-induced psoriasis have been limited to western countries while only a few cases have been reported in Korea and Japan. In addition, new onset of pustular psoriasis by TNF-alpha blocker has been reported more commonly than worsening of preexisting psoriasis. Now we report a patient whose preexisting psoriasis vulgaris was aggravated repeatedly after using the TNF-alpha blocker, infliximab, to control Crohn's disease, which is a rare rheumatologic disease in Korea.
随着越来越多的风湿病学家和皮肤科医生开始使用诸如肿瘤坏死因子-α阻滞剂等生物制剂，他们面临着一种意想不到的并发症：肿瘤坏死因子-α阻滞剂反而会使银屑病加重或诱发银屑病。尽管这并非肿瘤坏死因子-α阻滞剂的常见并发症，但这种加重情况可能比之前认为的更为普遍。据我们所知，大多数关于肿瘤坏死因子-α阻滞剂诱发银屑病的报道都局限于西方国家，而在韩国和日本仅有少数病例报道。此外，肿瘤坏死因子-α阻滞剂诱发脓疱型银屑病新发的报道比原有银屑病病情恶化更为常见。现在我们报告一例患者，其原有的寻常型银屑病在使用英夫利昔单抗（一种肿瘤坏死因子-α阻滞剂）控制克罗恩病（在韩国是一种罕见的风湿性疾病）后反复加重。
